• Home
    • Overview/Our mission
    • News and Events
    • Stock Quote
  • About us
    • At a glance
    • Our values
    • Management team
    • Board of Directors
    • Scientific Advisors
      • Cell Therapy Scientific Advisory Board
      • Glioblastoma Scientific Advisory Board
  • Science
    • NK Cell Derived Allogeneic Therapies
      • CHM 0201 (CORE-NK Platform)
      • CHM 0301 (Next Generation CORE-NK Platform)
      • CHM 1301 (CLTX CAR-NK)
      • CHM 2301 (CDH17 CAR-NK)
      • CHM 3301 (Undisclosed CAR-NK)
    • T Cell Derived Autologous Therapies
      • CHM 1101 (CLTX CAR T)
      • CHM 2101 (CDH17 CAR T)
    • Collaborations
    • About Cell Therapy
  • Pipeline
    • Overview
    • Clinical Trials
      • CHM 1101 (CLTX CAR T)
      • CHM 0201 (CORE-NK Platform)
    • Abstracts and Publications
  • News and Events
    • Press releases
    • Events and presentations
    • Media Coverage
    • Media Resources
  • Investors
    • Corporate Profile​
    • Investor News and Events
      • Annual Report
      • Press releases
      • Events and presentations
      • Analyst Coverage
      • Shareholder Newsletters
    • Stock information
      • Stock quote and chart
      • Historical price lookup
    • Corporate Governance
      • Corporate Charters
      • Corporate Policies
    • Resources
      • Investor Q and A
      • Email alerts
      • Investor Contacts
  • Careers
Menu
  • Home
    • Overview/Our mission
    • News and Events
    • Stock Quote
  • About us
    • At a glance
    • Our values
    • Management team
    • Board of Directors
    • Scientific Advisors
      • Cell Therapy Scientific Advisory Board
      • Glioblastoma Scientific Advisory Board
  • Science
    • NK Cell Derived Allogeneic Therapies
      • CHM 0201 (CORE-NK Platform)
      • CHM 0301 (Next Generation CORE-NK Platform)
      • CHM 1301 (CLTX CAR-NK)
      • CHM 2301 (CDH17 CAR-NK)
      • CHM 3301 (Undisclosed CAR-NK)
    • T Cell Derived Autologous Therapies
      • CHM 1101 (CLTX CAR T)
      • CHM 2101 (CDH17 CAR T)
    • Collaborations
    • About Cell Therapy
  • Pipeline
    • Overview
    • Clinical Trials
      • CHM 1101 (CLTX CAR T)
      • CHM 0201 (CORE-NK Platform)
    • Abstracts and Publications
  • News and Events
    • Press releases
    • Events and presentations
    • Media Coverage
    • Media Resources
  • Investors
    • Corporate Profile​
    • Investor News and Events
      • Annual Report
      • Press releases
      • Events and presentations
      • Analyst Coverage
      • Shareholder Newsletters
    • Stock information
      • Stock quote and chart
      • Historical price lookup
    • Corporate Governance
      • Corporate Charters
      • Corporate Policies
    • Resources
      • Investor Q and A
      • Email alerts
      • Investor Contacts
  • Careers
Linkedin-in Youtube Twitter Envelope
  • November 2016
  • Publications

Glioblastoma multiforme targeted therapy: The Chlorotoxin story

PrevPreviousChlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin
NextCurrent Biochemical Applications and Future Prospects of Chlorotoxin in Cancer Diagnostics and TherapeuticsNext
Share on facebook
Share on twitter
Share on linkedin
Sign-up to our mailing list to receive all the latest news from Chimeric Therapeutics
 
Please fill out our form for Investor Relations Inquiries
Investor Contacts
Linkedin-in Youtube Twitter Envelope